2016 ASCO Annual Meeting Abstract 8059: Healthcare Costs Among Multiple Myeloma (MM) Patients (Pts) Without Stem Cell Transplant (SCT)

MM Tx medications and tx of MM complications/AEs represent the majority of healthcare costs in MM pts. Monthly MM Tx medication costs were greatest for 4L+ and monthly total costs at treatment initiation were greatest for 1L. In each LOT monthly costs declined over time. Therapies that extend PFS and the treatment-free interval may reduce the costs of MM treatment and likely defer costs of subsequent MM tx.